Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, how this functional multiplicity relates to syntenin-1 distribution in different endosome compartments or other intracellular locations and its underlying involvement in cancer pathogenesis have yet to be fully defined.
|
31795513 |
2019 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
However, how this functional multiplicity relates to syntenin-1 distribution in different endosome compartments or other intracellular locations and its underlying involvement in cancer pathogenesis have yet to be fully defined.
|
31795513 |
2019 |
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
UNC93B1 recruits syntenin-1 to dampen TLR7 signalling and prevent autoimmunity.
|
31546246 |
2019 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Genetic (shmda-9, mda-9 siRNA) or pharmacological (small molecule inhibitor of protein-protein interactions; PDZ1i) blockade of MDA-9 decreases NB migration, invasion, and metastasis.
|
31406249 |
2019 |
Secondary malignant neoplasm of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
NB cell lines and clinical samples display elevated MDA-9 expression and bioinformatic analysis supports an association between elevated MDA-9 and bone metastasis and poor prognosis.
|
31406249 |
2019 |
stage, neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We identify MDA-9 as a key contributor to NB pathogenesis and show that genetic or pharmacological inhibition suppresses NB pathogenesis by an integrin-mediated Src-disruption pathway.
|
31406249 |
2019 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review focuses on a unique gene, melanoma differentiation associated gene-9 (also known as Syntenin-1; Syndecan Binding Protein (sdcbp); mda-9/syntenin), initially cloned and characterized from metastatic human melanoma and shown to be a pro-metastatic gene.
|
31349898 |
2019 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MDA-9/Syntenin: An emerging global molecular target regulating cancer invasion and metastasis.
|
31349898 |
2019 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Metastasis is the primary determinant of death in patients with diverse solid tumors and MDA-9/Syntenin (SDCBP), a pro-metastatic and pro-angiogenic gene, contributes to this process.
|
31345950 |
2019 |
Malignant neoplasm of prostate
|
0.020 |
Biomarker
|
disease |
BEFREE |
These observations firmly established MDA-9/Syntenin as a potential molecular target in prostate cancer.
|
31345950 |
2019 |
Prostate carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
These observations firmly established MDA-9/Syntenin as a potential molecular target in prostate cancer.
|
31345950 |
2019 |
Solid Neoplasm
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Metastasis is the primary determinant of death in patients with diverse solid tumors and MDA-9/Syntenin (SDCBP), a pro-metastatic and pro-angiogenic gene, contributes to this process.
|
31345950 |
2019 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Thus, our clinical patient cohort and functional data suggest that miR-135b-5p/SDCBP is a crucial determinant of BC metastasis at a very early stage.
|
31024042 |
2019 |
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
Thus, our clinical patient cohort and functional data suggest that miR-135b-5p/SDCBP is a crucial determinant of BC metastasis at a very early stage.
|
31024042 |
2019 |
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Thus, our clinical patient cohort and functional data suggest that miR-135b-5p/SDCBP is a crucial determinant of BC metastasis at a very early stage.
|
31024042 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The objective of this review is to provide a current perspective on the cancer-specific role of MDA-9/Syntenin in order to explore its potential for cancer drug discovery and cancer therapy.
|
30766662 |
2019 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma differentiation-associated gene 9 (MDA-9)/Syntenin is a multidomain PDZ protein and identified as a key oncogene in melanoma initially.
|
30766662 |
2019 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The objective of this review is to provide a current perspective on the cancer-specific role of MDA-9/Syntenin in order to explore its potential for cancer drug discovery and cancer therapy.
|
30766662 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In some cases, its role in cancer biology depends on relationships between MDA-9/Syntenin and NF-κB.
|
30608040 |
2018 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of MDA-9/Syntenin occurs in multiple human cancer cell lines and is associated with higher grade of tumor classification, invasiveness and metastasis.
|
30608040 |
2018 |
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Interestingly, in all cell lines, inhibition of MDA- 9/Syntenin expression induced NF-κB downregulation and contemporary a reduction in invasion ability MMP-2 dependent.
|
30608040 |
2018 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In some cases, its role in cancer biology depends on relationships between MDA-9/Syntenin and NF-κB.
|
30608040 |
2018 |
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Overexpression of MDA-9/Syntenin occurs in multiple human cancer cell lines and is associated with higher grade of tumor classification, invasiveness and metastasis.
|
30608040 |
2018 |
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We have examined basal expression of MDA-9/Syntenin in three cell lines of human liver carcinoma (HA22T/VGH, Hep3B and HepG2).
|
30608040 |
2018 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we hypothesized that microRNA-23a (miR-23a) affects the cell proliferation, migration, and invasion of melanoma with a mechanism related to SDCBP and the MAPK/ERK signaling pathway.
|
30589231 |
2019 |